Liraglutide LL
GLP-1R agonist
GLP-1 receptor agonist, a fatty-acid-modified analogue of human GLP-1, studied for insulin secretion, beta-cell function and appetite signalling.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GLP-1R agonist
- Category
- Metabolic & Incretin
- Type
- Single compound
- Abbreviation
- LL
- Development and regulatory status
- Approved prescription drug (type 2 diabetes, obesity)
What researchers study
Liraglutide is a GLP-1 receptor agonist, a fatty-acid-modified analogue of human GLP-1 with an extended duration of action. It is studied for insulin secretion, beta-cell function and appetite signalling.
Research areas
- GLP-1 receptor signalling and beta-cell function
- Insulin secretion and glucose handling in models
- Appetite regulation and body-weight studies
- Cardiovascular outcome research
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 3 trial
In SCALE Obesity, 3,731 adults with obesity had mean weight loss of 8.4% at 56 weeks versus 2.8% with placebo
- phase 3 trial
In LEADER (9,340 adults with type 2 diabetes at high cardiovascular risk), primary composite events occurred in 13.0% versus 14.9% with placebo
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Semaglutidelonger-acting GLP-1 receptor agonist for comparative pharmacology
- DulaglutideFc-fusion GLP-1 agonist for comparative pharmacology
- Cagrilintideamylin analogue tested against liraglutide in a phase 2 comparison
